Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat

Quittet, Marie-Sophie; Touzani, Omar; Sindji, Laurence; Cayon, Jérôme; Fillesoye, Fabien; Toutain, Jérôme; Divoux, Didier; Marteau, Léna; Lecocq, Myriam; Roussel, Simon; Montero‐Menei, Claudia N.; Bernaudin, Myriam

doi:10.1016/j.actbio.2014.12.017

Cited by 40 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This strategy achieved prolonged vascular endothelial growth factor ( VEGF ) release, increasing angiogenesis around the implantation site and supporting the migration of immature neurons towards the ischemic site. 127 …”

Section: Therapeutic Potential Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System

et al. 2016

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a group of fibroblast-like multipotent mesenchymal stromal cells that have the ability to differentiate into osteoblasts, adipocytes, and chondrocytes. Recent studies have demonstrated that MSCs possess a unique ability to exert suppressive and regulatory effects on both adaptive and innate immunity in an autologous and allogeneic manner. A vital step in stem cell transplantation is overcoming the potential graft-versus-host disease, which is a limiting factor to transplantation success. Given that MSCs attain powerful differentiation capabilities and also present immunosuppressive properties, which enable them to survive host immune rejection, MSCs are of great interest. Due to their ability to differentiate into different cell types and to suppress and modulate the immune system, MSCs are being developed for treating a plethora of diseases, including immune disorders. Moreover, in recent years, MSCs have been genetically engineered to treat and sometimes even cure some diseases, and the use of MSCs for cell therapy presents new perspectives for overcoming tissue rejection. In this review, we discuss the potential extrinsic and intrinsic mechanisms that underlie MSCs’ unique ability to modulate inflammation, and both innate and adaptive immunity.

show abstract

Section: Therapeutic Potential Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System

et al. 2016

View full text Add to dashboard Cite

show abstract

“…VEGF has reported to be a key factor in promoting angiogenesis (42). A number of studies have reported that VEGF has an important role in promoting proliferation, migration and chemotactic response in bone, lung, kidney, brain, vascular endothelial cells, tumor and other tissues (43)(44)(45)(46)(47)(48). Under pathological conditions, hypoxia is the main factor that promotes the synthesis of VEGF (49).…”

Section: Discussionmentioning

confidence: 99%

Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells

Zhang

Luo

2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Lymphatic and hematogenous spread are the most common ways for tumors to metastasize. Angiogenesis is essential for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) particularly VEGF-A is important in the process of angiogenesis. The current research has indicated that thalidomide (THD) may be able to inhibit angiogenesis, stimulate the activity of the immune system and inhibit the adherence of cancer cells to stromal cells. These changes may lead to suppression of tumor occurrence and development. To date, to the best of our knowledge, the effects of THD on colon cancer SW480 cells have not been reported. In the present study, the effects of THD and a combination of THD and oxaliplatin (L-OHP) on the proliferation of SW480 cells have been investigated. Furthermore, the expression of VEGF-A and hypoxia-inducible factor 1 (HIF-1) was analyzed using MTT assay, quantitative polymerase chain reaction and western blot analysis. The results indicated that THD was able to inhibit SW480 cells in dose-and-time dependent manner and inhibit the expression of VEGF-A and HIF-1α. Furthermore, treatment with THD and L-OHP had synergistic inhibitory effect, which may provide a novel treatment strategy for advanced colorectal cancer.

show abstract

“…One of the most used biomaterial‐based nanostructures in the combinational studies are the polymeric ones. These nanostructures find several uses as supportive scaffolds for the delivery of MSCs, as nanoparticles for drug and gene delivery or as coatings for inorganic nanoparticles . Each of these nanostructures is able to encapsulate a variety of therapeutics, including antioxidants such as catalase,86a nanoceria, and edaravone, growth factors such as VEGF, and other neuroprotectants such as glyburide86b and the NR2B9C therapeutic peptide 86c.…”

Section: Combinational Approachesmentioning

confidence: 99%

Advanced Functional Materials and Cell‐Based Therapies for the Treatment of Ischemic Stroke and Postischemic Stroke Effects

Tapeinos

Larrañaga

Tomatis

et al. 2019

Adv Funct Materials

View full text Add to dashboard Cite

Ischemic stroke is considered one of the most threatening neurological disorders with high percentages of mortality and morbidity worldwide. Although in recent years, several nanotechnological advances have improved the survival rates, severe untreated poststroke side‐effects continue to significantly influence the way of life of many. Tissue plasminogen activator and mechanical thrombectomy are considered the gold standards for the treatment of acute cerebral ischemia. These, however, fail to improve postischemic disorders. Herein, after a brief description of the pathophysiology of ischemic stroke and the following biochemical cascade, the most recent biomaterial and cell‐based strategies are reviewed for its treatment. Other therapeutics that have been proposed not only for the treatment of cerebral ischemia but also for the regeneration of the infarcted brain that is responsible for a variety of disorders, including cognitive, motor, and speech problems are also presented. Finally, a few reported studies on diagnostic and theranostic nanostructures are also provided.

show abstract

Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat

Cited by 40 publications

References 41 publications

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System

Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System

Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells

Advanced Functional Materials and Cell‐Based Therapies for the Treatment of Ischemic Stroke and Postischemic Stroke Effects

Contact Info

Product

Resources

About